Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Company Overview

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations. By combining nucleoside‐modified mRNA with bespoke LNP carriers, the company seeks to enhance cellular uptake and reduce immunogenicity, positioning its pipeline candidates for both systemic and localized therapeutic interventions. Cartesian’s preclinical programs include immuno-modulatory candidates intended to boost anti-tumor immunity, as well as mRNA constructs designed to reestablish immune tolerance in autoimmune disease models. The firm has also entered strategic collaborations with academic institutions and contract research organizations to support IND-enabling studies and expand its translational research capabilities.

Founded as a spin-out from leading academic research laboratories, Cartesian Therapeutics completed its initial public offering in 2021. Headquartered in New Jersey, the company engages with a broad network of scientific and clinical partners across North America and Europe. Cartesian’s leadership team includes experienced executives drawn from both biotech start-ups and larger pharmaceutical organizations, underscoring its commitment to advancing mRNA science from bench to bedside. As Cartesian progresses toward clinical milestones, it aims to establish itself as a key innovator in the rapidly evolving field of RNA therapeutics.

Key Stats

• Today's Range: $9.90 to $10.34
• 50-Day Range: $9.15 to $13.70
• 52-Week Range: $8.46 to $26.50
• Volume: 30,378 shs
• Average Volume: 79,458 shs
• Market Capitalization: $267.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Moderate Buy

Cartesian Therapeutics Stock Analysis - MarketRank™

Cartesian Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 687th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Cartesian Therapeutics has a consensus price target of $40.00, representing about 299.2% upside from its current price of $10.02.

Amount of Analyst Coverage

Cartesian Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cartesian Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cartesian Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.64% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cartesian Therapeutics does not currently pay a dividend.

Dividend Growth

Cartesian Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.64% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Cartesian Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RNAC Stock Analysis - Frequently Asked Questions

How have RNAC shares performed this year?

Cartesian Therapeutics' stock was trading at $17.91 at the beginning of the year. Since then, RNAC shares have decreased by 44.1% and is now trading at $10.02.

How were Cartesian Therapeutics' earnings last quarter?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of ($0.76) by $1.26. The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.77 million.

When did Cartesian Therapeutics' stock split?

Cartesian Therapeutics's stock reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Cartesian Therapeutics?

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cartesian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAC
• Previous Symbol: NASDAQ:RNAC
• CIK: 1453687
• Web: selectabio.com
• Phone: 617-923-1400
• Fax: 617-924-3454
• Employees: 64
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Cartesian Therapeutics: $40.00
• High Price Target: $42.00
• Low Price Target: $38.00
• Potential Upside/Downside: +299.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($52.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 2.20
• P/E Growth: N/A
• Net Income: -$77.42 million
• Net Margins: N/A
• Pretax Margin: -3,506.15%
• Return on Equity: N/A
• Return on Assets: -6.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.33
• Quick Ratio: 13.33

Sales & Book Value

• Annual Sales: $38.91 million
• Price / Sales: 6.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -37.11

Miscellaneous

• Outstanding Shares: 26,000,000
• Free Float: 10,323,000
• Market Cap: $260.52 million
• Optionable: Optionable
• Beta: 0.39